PRE 14A

PRIMARY DOCUMENT

Company: NRX Pharmaceuticals, Inc.
Filed: November 25, 2020
Period of Report: December 18, 2020
Accession Number: 0001654954-20-012931

View Document ↗ View on SEC.gov ↗